Enanta Pharmaceuticals financials

Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.

USD	FY, 2013	FY, 2014	FY, 2015	FY, 2016	FY, 2017	FY, 2018	FY, 2019	FY, 2021
Revenue	32.1M	47.7M	160.9M	88.3M	102.8M	206.6M	205.2M	97.1M
Revenue growth, %		48.9%	237.0%	-45.1%
General and administrative expense	6.2M	10.0M	13.5M	17.0M	20.7M	23.4M	26.2M	32.5M
Operating expense total	23.0M	28.8M	36.7M	57.4M	78.2M	118.3M	168.5M
EBIT	9.0M	19.0M	124.1M	30.8M	24.6M	88.3M	36.7M	(109.6M)
EBIT margin, %	28.2%	39.8%	77.2%	34.9%	23.9%	42.7%	17.9%
Interest income	248.0K	467.0K	968.0K	1.7M	2.5M
Interest expense	598.0K	283.0K	1.3M	1.7M	2.3M	4.9M	8.8M	2.0M
Pre tax profit	9.6M	19.3M	125.5M	32.6M	26.9M	93.1M	45.6M	(107.6M)
Income tax expense		(15.2M)	46.5M	10.9M	9.2M	21.2M	(826.0K)	(28.6M)
Net Income	9.6M	34.4M	79.0M	21.7M	17.7M	72.0M	46.4M	(79.0M)

Footer menu